Navigation Links
Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response

s Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the timing and scope of clinical studies and trials for nab-rapamycin mTOR inhibitor (ABI 009), and nab-17AAG HSP90 inhibitor (ABI 010). Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the fact that results from pre-clinical studies may not be predictive of results to be obtained in other pre-clinical studies or future clinical trials, delays in commencement and completion of clinical trials, including slower than anticipated patient enrollment and adverse events occurring during the clinical trials, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of pharmaceutical products, the ability to successfully manufacture products in a time-sensitive and cost effective manner, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties. Additional relevant information concerning risks can be found in Abraxis BioScience's Form 10-K for the year ended December 31, 2006 and other documents it has filed with the Securities and Exchange Commission.

The information contained in this press release is as of the date of this release. Abraxis assumes no obligations to update any forward-looking statements contained in this press release as the result of new information or future events or developments.

Avastin(R) (bevacizumab) is a registered trademark of Genentech Inc.

Taxol(R) (paclitaxel) is a registered trademark of Bristol-Myers Squibb Co
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") ... it has received commitments from institutional investors to ... the Company,s common stock in an at-the-market registered ... fund. The Company entered into definitive ... the Company agreed to sell an aggregate of ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... Trading (OFT) approval condition to the announced tender offer for ...   As a result of the waiver, the ... expects to complete the tender offer on January 24, 2014 ... of all of the remaining conditions to the tender offer. ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ... Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... , RIDGEFIELD, Conn., Aug. 25 Results of ... Warfarin, Compared to Dabigatran)(1) study will be presented at the ... Aug. 30. The primary objective of RE-LY was to ... thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, ...
... August 25 20% of parents seek medical,help because ... baby,and the accompanying discomfort (crying). Reputed medical journal "Archives,of ... recently,published the results of the clinical research project that ... department of the Brussels,University Hospital. , ...
Cached Medicine Technology:Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 2Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 3Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 4Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 5Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 6Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 7Medical World Recognises New Therapy for Reflux Babies 2
(Date:4/14/2014)... dense, urban centers around the world, many people live ... tall buildings that block sunlight. And as the global ... together, the darkness will only spread. , To ... translucent panel that redirects sunlight onto narrow streets and ... over the edge at an angle, where it spreads ...
(Date:4/14/2014)... professor of chemical engineering at Virginia Tech , ... analyze living cells. The long-term goal is to gain ... In his lab , Lu and his students ... events inside cells. These devices promote high sensitivity and ... cells. , Based on their record of achievements, the ...
(Date:4/14/2014)... April 2014, Perth, Australia. Drug discovery company Proteomics ... development of a companion diagnostic (CDx) test with ... , The research team authenticated the panel of ... control samples. Seven biomarkers were validated at high ... , The mass spectrometry data was then cross-validated ...
(Date:4/14/2014)... for high-risk bladder cancer, chemotherapy before or after ... practice. The findings are published early online in ... American Cancer Society. , Clinical trials have shown ... bladder cancer who are given chemotherapy before surgery. ... surgery also improves survival. To investigate the use ...
(Date:4/11/2014)... control brain cell production could pave the way for ... Scientists have gained new understanding of the role played ... nerve and brain cells are formed a process ... healthy. Their findings could help explain what happens when ... fundamental characteristic of many diseases including cancer. , ...
Breaking Medicine News(10 mins):Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2
... HealthDay Reporter , THURSDAY, Sept. 16 (HealthDay News) -- ... cancer, new research finds. Prior research has shown higher ... this study is among the first to show that lower ... as gastrointestinal bleeding -- may also be effective, said Eric ...
... of fertilizer that feeds breast cancer progression, significantly ... researchers at UCLA,s Jonsson Comprehensive Cancer Center have ... the immune cells that are trying to fight ... the body against disease into aiders and abettors. ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... Wednesday over whether the diet drug Meridia should be pulled ... risk of heart attack and stroke. Members of an ... said the drug should remain available to consumers called for ...
... Reporter , WEDNESDAY, Sept. 15 (HealthDay News) -- Children with ... that is, yawn in response to seeing others yawn, a ... contagion," an unconscious response that reflects a recognition of how ... and others is an important step in a child,s social ...
... WEDNESDAY, Sept. 15 (HealthDay News) -- When people with chronic ... the level of hemoglobin cells in their blood should go ... levels don,t increase by much, these "poor responders" experience a ... Reporting in the Sept. 16 issue of the New ...
... Center at the University of California, San Diego has ... the American College of Radiology (ACR). ... and this prestigious certificate recognizes our extraordinary effort," said ... Moores UCSD Cancer Center. "ACR leads the way toward ...
Cached Medicine News:Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 2Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 3Health News:Stress accelerates breast cancer progression in mice 2Health News:Stress accelerates breast cancer progression in mice 3Health News:Stress accelerates breast cancer progression in mice 4Health News:FDA Advisers Divided on Whether to Ban Diet Drug Meridia 2Health News:FDA Advisers Divided on Whether to Ban Diet Drug Meridia 3Health News:Autistic Children Don't Seem to Yawn 'Contagiously' 2Health News:Autistic Children Don't Seem to Yawn 'Contagiously' 3Health News:Anemia Drugs Could Pose Threat to Some Kidney Patients 2Health News:Anemia Drugs Could Pose Threat to Some Kidney Patients 3
... FloSeal is a prorietary combination of ... FloSeal is a high viscosity gel for ... capillary oozing to arterial spurting. FloSeal is ... to haemostasis when control of bleeding by ...
... gives you new options for skin wound ... application only to hold closed easily approximated ... including punctures from minimally invasive surgery, and ... may be used in conjunction with, but ...
... Indermil® tissue adhesive is indicated for the ... incisions, and trauma-induced lacerations in areas of ... and have easily approximated skin edges. In ... adhesive may act as a barrier to ...
... office to eliminate paper completely without ... functions. With PT Medical's digital ... add digital signatures to informed consents, ... that require a patient, doctor, or ...
Medicine Products: